SCHEMBL23744102

SCHEMBL23744102

C[C@@H]1CN(c2cnc3cc(F)ccc3n2)[C@@H](C)CN1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.40
HDAC1 Q13547 1/20 0.38
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.37
PIM1 P11309 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC2 Q92769 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
HCRTR1 O43613 3/20 0.34
HCRTR2 O43614 3/20 0.34
HCAR2 Q8TDS4 1/20 0.34
ATR Q13535 1/20 0.34
ATRIP Q8WXE1 1/20 0.34
TLR9 Q9NR96 4/20 0.33
TLR8 Q9NR97 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30345489 1.00 MCHR1 (0.40) MCHR1HDAC1ROCK2ROCK1PIM1
SCHEMBL30345740 0.85 MCHR1 (0.42) MCHR1HDAC1ROCK2ROCK1PIM1
SCHEMBL23744803 0.85 MCHR1 (0.42) MCHR1HDAC1ROCK2ROCK1PIM1
SCHEMBL23744103 0.83 MCHR1 (0.42) MCHR1HDAC1ROCK2ROCK1PIM1
SCHEMBL13666118 0.83 HCAR2 (0.46) HDAC1ROCK2ROCK1PIM1MEN1
SCHEMBL23744797 0.79 ACVR1 (0.47) MCHR1PIM1MEN1NPC1RAB9A
SCHEMBL23744100 0.78 ROCK2 (0.44) MCHR1ROCK2ROCK1PIM1SIGMAR1
SCHEMBL30345601 0.78 ROCK2 (0.44) MCHR1ROCK2ROCK1PIM1SIGMAR1
SCHEMBL23744193 0.77 MEN1 (0.43) MCHR1MEN1NPC1RAB9AKMT2A
SCHEMBL23744192 0.77 MEN1 (0.43) MCHR1MEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 MCHR1 134/4885HDAC1 1545/4885ROCK2 2599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.